MedPage Today on MSN21h
De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBC
Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...
Zacks Investment Research on MSN1d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
The American Journal of Managed Care2d
With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key”
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
The Pharma Letter4d
New EC approval for BMS’ Opdivo and Yervoy
US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus ...
Targeted Oncology10h
Peers Discuss Management of IO/TKI Toxicities and Dosing Strategies in Frontline RCC
Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...
CURE5d
Presurgical Opdivo Plus Yervoy Has Potential Clinical Benefit in NSCLC
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...
Pharmabiz1d
European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC
European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...
Medical Dialogues2d
Bristol Myers Squibb gets European Commission nod for Opdivo plus Yervoy for Hepatocellular Carcinoma
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy ...
Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait?
BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Targeted Oncology8d
Understanding the Use of Nivolumab in the Current Upper GI Landscape
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...